Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (Details)

v2.4.0.8
STOCKHOLDERS' EQUITY (Details) (USD $)
 0 Months Ended 0 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Feb. 04, 2008
Nov. 07, 2007
Dec. 31, 2013
Dec. 31, 2009
Feb. 04, 2008
Warrants [Member]
Nov. 07, 2007
Warrants [Member]
Dec. 31, 2013
Warrants [Member]
Dec. 31, 2013
2012 Series B private placement [Member]
Dec. 31, 2012
2012 investor relations advisor [Member]
Dec. 31, 2013
2012 investor relations advisor [Member]
Dec. 31, 2013
2011 November Private Placement (1) [Member]
Dec. 31, 2013
2011 November Private Placement (1) [Member]
Warrants [Member]
Dec. 31, 2013
2011 November Private Placement (1) [Member]
Warrant2 [Member]
Dec. 31, 2013
2011 November Private Placement (2) [Member]
Dec. 31, 2013
2011 November Private Placement (2) [Member]
Warrants [Member]
Dec. 31, 2013
2011 November Private Placement (2) [Member]
Warrant2 [Member]
Dec. 31, 2013
2011 November Placement Agent Warrants [Member]
Dec. 31, 2013
2011 November Placement Agent Warrants [Member]
Warrants [Member]
Dec. 31, 2013
2011 November Placement Agent Warrants [Member]
Warrant2 [Member]
Dec. 31, 2013
2011 Investor Relations Advisor 1 [Member]
Dec. 31, 2013
2010 December Registered Direct Offering [Member]
Dec. 31, 2013
2010 January Registered Direct Offering [Member]
Dec. 31, 2013
2010 January Placement Agent Warrants [Member]
Dec. 31, 2013
2009 Investor Relations Advisor [Member]
Dec. 31, 2010
2009 Business Consultant [Member]
Dec. 31, 2013
2009 Business Consultant [Member]
Dec. 31, 2009
2009 Business Consultant [Member]
Dec. 31, 2013
2008 Preferred Stock Offering [Member]
Dec. 31, 2011
2008 Preferred Stock Offering [Member]
Dec. 31, 2010
2008 Preferred Stock Offering [Member]
Dec. 31, 2009
2008 Preferred Stock Offering [Member]
Dec. 31, 2013
2008 Somanta Accounts Payable [Member]
Dec. 31, 2013
2006 Convertible Note 1 [Member]
Dec. 31, 2013
2006 Convertible Note 2 [Member]
Dec. 31, 2013
2006 Convertible Note 3 [Member]
Dec. 31, 2013
2006 Convertible Notes [Member]
Dec. 31, 2013
2006 Convertible Notes [Member]
Warrants [Member]
Class of Warrant or Right [Line Items]                                                                          
Warrants Outstanding (in shares)     31,879,063         20,000,000 [1]   30,000 [2] 2,144,656 [3] 1,857,156 287,500 2,144,656 [3] 1,857,156 287,500 36,893 [3] 18,447 18,446 12,500 [4] 930,664 [5] 1,041,432 [6] 125,109 [6] 25,000 [7]   60,000 [8]   499,584 [9]       246,753 [10] 3,818,180 [11] 386,364 [11] 377,272 [11] 4,581,816  
Exercise Price (in dollars per share)       $ 3.50       $ 0.50 [1]   $ 1.17 [2] $ 1.67 [3]     $ 2.00 [3]       $ 1.67 [3] $ 2.00 [3] $ 2.30 [4] $ 3.06 [5] $ 3.00 [6] $ 3.75 [6] $ 3.50 [7]   $ 2.07 [8]   $ 0.50 [9]       $ 3.50 [10] $ 1.32 [11] $ 1.32 [11] $ 1.32 [11]    
Expiration Date                     5/2010 & 30/2014 [3]     11/2010 & 30/2016 [3]     11/2010 & 30/2016 [3]                                        
Expiration Date               Oct. 24, 2018 [1]   Apr. 19, 2014 [2] May 10, 2014     Nov. 10, 2016     Nov. 10, 2016     Apr. 15, 2014 [4] Dec. 14, 2015 [5] Jan. 26, 2015 [6] Jan. 26, 2015 [6] Nov. 04, 2014 [7]   Jul. 23, 2014 [8]   Feb. 04, 2014 [9]       Jan. 04, 2014 [10] Feb. 16, 2015 [11] Oct. 24, 2015 [11] Dec. 06, 2015 [11]    
Exercisable period of warrants 6 years 6 years                                                                   6 years  
Investor relations consulting services expense                 $ 10,000                                                        
Fair value of warrants (in dollars per share) $ 2.29 $ 2.59 $ 3.50                                                 $ 2.29                  
Expected dividend yield (in hundredths)         0.00% 0.00%                                           0.00%                  
Risk-free interest rate (in hundredths)         2.75% 3.84%                                           2.75%                  
Expected volatility rate (in hundredths)         110.00% 110.00%                                           110.00%                  
Expected term         6 years 6 years 6 years                                         6 years                  
Warrants received by investor relation advisor to purchase common stock (in shares)     3,895,047                                               150,000                    
Warrants expired (in shares)                                                 90,000                        
Decreased exercise price of warrants (in dollars per share)                                                       $ 0.50 $ 1.45 $ 2.55 $ 3.00            
Purchase price of Somanta Pharmaceuticals Inc.                                                               $ 1,576,000          
Number of common shares issued in acquisition (in shares)                                                               538,508          
Warrants extended exercisable period                                                                         3 years
[1] In connection with a private placement offering on October 25, 2012, warrants to purchase 20,000,000 shares of common stock at $0.50 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.
[2] During 2012, an investor relations advisor received warrants to purchase 30,000 shares of common stock at an exercise price of $1.17 per share exercisable at any time until April 19, 2014, for investor relations consulting services rendered in 2012. The expense recorded for the year ended December 31, 2012 was $10,000.
[3] In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 2,144,656 shares of common stock at $1.67 per share were issued. All of the warrants are exercisable immediately and 1,857,156 warrants expire May 10, 2014 and 287,500 warrants expire May 30, 2014. In connection with a private placement offering on November 10 and 30, 2011, additional warrants to purchase 2,144,656 shares of common stock at $2.00 per share were issued. All of the warrants are exercisable immediately and 1,857,156 warrants expire November 10, 2016 and 287,500 warrants expire November 30, 2016. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 18,447 shares of common stock at $1.67 per share were issued. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 18,446 shares of common stock at $2.00 per share were issued. All the placement agent warrants are exercisable immediately and 18,447 warrants expire November 10, 2016 and 18,446 warrants expire November 30, 2016.
[4] During 2011, an investor relations advisor received warrants to purchase 12,500 shares of common stock at an exercise price of $2.30 per share at any time until April 15, 2014, for investor relations consulting services rendered in 2011.
[5] In connection with a registered direct offering on December 14, 2010, warrants to purchase 930,664 shares of common stock at $3.06 per share were issued. All of the warrants are exercisable immediately and expire December 14, 2015.
[6] In connection with a registered direct offering on January 26, 2010, warrants to purchase 1,041,432 shares of common stock at $3.00 per share were issued. All of the warrants are exercisable immediately and expire January 26, 2015. In addition, we issued warrants for placement agent fees to purchase 125,109 shares of our common stock at an exercise price of $3.75 per share. All of the warrants are exercisable immediately and expire January 26, 2015.
[7] During 2010, an investor relations advisor received warrants to purchase 25,000 shares of common stock at an exercise price of $3.50 per share at any time until November 4, 2014, for investor relations consulting services rendered in 2010.
[8] During 2009, a business consultant received warrants to purchase 150,000 shares of common stock at an exercise price of $2.07 per share at any time until July 23, 2014, for business consulting services rendered in 2009. 60,000 of the warrants were exercisable on December 31, 2011. The remaining 90,000 warrants expired July 23, 2010 because our stock did not reach specified trading prices.
[9] In connection with the preferred stock offering in February 2008, warrants to purchase a total of 499,584 shares of common stock were issued. All of the warrants expired February 4, 2014. The fair value of the warrants was $2.29 per share on the date of the grant using the Black-Scholes pricing model with the following assumptions: expected dividend yield 0.0%, risk-free interest rate 2.75%, expected volatility 110% and a term of 6 years. The exercise price of $3.50 was decreased to $3.00 after the January 2010 placement; to $2.55 after the December 2010 placement; to $1.45 after the November 2011 placement; and, to $0.50 after the October 2012 placement.
[10] In connection with our acquisition of Somanta Pharmaceuticals, Inc. (Somanta) we exchanged for $1,576,000 due to Somanta vendors, for 538,508 shares of our common stock and warrants to purchase 246,753 shares of common stock at $3.50. The warrants expired January 4, 2014.
[11] In connection with the convertible note offerings in 2006, warrants to purchase a total of 4,581,816 shares of common stock at $1.32 per share were issued. All of the warrants are exercisable immediately and expire six years from date of issue. On February 10, 2012 these warrants were extended an additional three years.